Hoth Therapeutics, Inc. (HOTH) Insider Trading Activity

NASDAQ$1.2
Market Cap
$15.91M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
573 of 827
Rank in Industry
327 of 469

HOTH Insider Trading Activity

HOTH Median Price and Trade Amounts History Chart

Statistics of Insider Transactions

Amount of Insider Buys and Sells

Buys
$0
0
Sells
$0
0

Related Transactions

About Hoth Therapeutics, Inc.

Hoth Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-003 to treat inflammatory bowel diseases, as well as acne and psoriasis; HT-004 for treatment of asthma and allergies using inhalational administration; HT-006 to treat lung diseases resulting from bacterial infections; and HT-002, a novel peptide for treating COVID-19. The company is also developing BioLexa Platform, a proprietary, patented, drug compound platform which is in phase I clinical trial for the treatment of eczema; and HT-005 for treating patients with lupus. The company has license agreements with the George Washington University; the University of Maryland; Isoprene Pharmaceuticals, Inc.; the North Carolina State University; Chelexa BioSciences, Inc.; Zylö Therapeutics, Inc., and the University of Cincinnati. It also has a research collaboration agreement with Weill Cornell Medicine to develop HT-003. Hoth Therapeutics, Inc. was incorporated in 2017 and is headquartered in New York, New York.

Insider Activity of Hoth Therapeutics, Inc.

Over the last 12 months, insiders at Hoth Therapeutics, Inc. have bought $0 and sold $0 worth of Hoth Therapeutics, Inc. stock.

On average, over the past 5 years, insiders at Hoth Therapeutics, Inc. have bought $16,750 and sold $0 worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 25,000 shares for transaction amount of $16,750 was made by Knie Robb (CEO and President) on 2024‑08‑16.

List of Insider Buy and Sell Transactions, Hoth Therapeutics, Inc.

2024-08-16PurchaseKnie RobbCEO and President
25,000
0.5041%
$0.67
$16,750
+32.10%
2020-05-26SaleHayes Anthony
0
$0
$0
-25.09%
Total: 2

Insider Historical Profitability

32.1%
Knie RobbCEO and President
58131
0.4384%
$69,757.2010
+32.1%
Hayes Anthony
0
0%
$001

Historical Insider Profitability vs. Competitors

$53,490,060
55
19.35%
$14.87M
$17,168,388
54
-43.55%
$13.86M
$555,628
21
43.52%
$16.89M
$1,616,354
20
-12.22%
$18.43M
$53,355
19
-41.05%
$14.1M
$613,181
18
-20.90%
$15.75M
$112,810,270
18
-1.20%
$14.25M
$25,487,383
15
-4.37%
$17.45M
$112,908,886
15
-2.59%
$15.58M
$4,146,041
11
-40.86%
$15.26M
$11,777,042
10
-11.94%
$13.19M
$147,504
5
-36.70%
$21.13M
$87,925
5
-18.56%
$19.19M
$1,184,658
4
-22.17%
$14.9M
$14,530
3
62.23%
$16.23M
Hoth Therapeutics, Inc.
(HOTH)
$16,750
1
32.10%
$15.91M
$3,750
1
-33.13%
$18.46M
$500,000
1
-22.94%
$16.95M
$30,190
1
-42.39%
$17.38M

HOTH Institutional Investors: Active Positions

Increased Positions20+166.67%1M+417.72%
Decreased Positions4-33.33%35,905-13.55%
New Positions13New830,861New
Sold Out Positions2Sold Out30,000Sold Out
Total Postitions28+133.33%1M+404.17%

HOTH Ownership Change vs Market

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
Renaissance Technologies Llc$295.001.53%243,921+243,921New2025-09-30
Vanguard Group Inc$259.001.34%214,009+175,205+451.51%2025-09-30
Geode Capital Management, Llc$186.000.96%153,535+30,960+25.26%2025-09-30
Citadel Advisors Llc$174.000.9%143,473+143,473New2025-09-30
Virtu Financial Llc$137.000.71%113,412+113,412New2025-09-30
Ubs Group Ag$115.000.59%94,665+52,425+124.11%2025-09-30
Hrt Financial Lp$103.000.53%85,332+85,332New2025-09-30
State Street Corp$77.000.4%63,939+63,939New2025-09-30
Jane Street Group, Llc$66.000.34%54,940+54,940New2025-09-30
Northern Trust Corp$50.000.26%41,504+41,504New2025-09-30

Financial Ratios

Summary
Comparison with Competitors

Price to Earnings

Price/Earnings to Growth

Price to Sales

Price to Book

Price/Free Cash Flow

Analyst Recommendations

Analyst Price Targets

No data is available at this moment.
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.